CD274 and non-small cell lung carcinoma: CA-170, targeting both VISTA and PD-L1 in a phase 2 trial, showed a clinical benefit rate of 75% and progression-free survival of 19.5 weeks in patients with nonsquamous non-small cell lung cancer (NSCLC) [43].